Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Jarvis

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Journal of Sexual Medicine|July 22, 2025
Mindfulness and daily sexual function: a dyadic diary studyEmily Jarvis, Jackie S Huberman, Natalie O Rosen
Clinical Therapeutics|July 30, 2018
Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy SubjectsRobert Wilson, Emily Jarvis, Mickael Montembault, et al.
Contemporary Clinical Trials Communications|December 16, 2025
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3Florian Wagenlehner, Keith S Kaye, David A Talan, et al.
Respiratory Research|May 13, 2022
Mass spectrometry detection of inhaled drug in distal fibrotic lungTheresia A Mikolasch, Eunice Oballa, Mitra Vahdati-Bolouri, et al.
Lancet (London, England)|February 11, 2024
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trialsFlorian Wagenlehner, Caroline R Perry, Thomas M Hooton, et al.
Future Microbiology|February 24, 2025
Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infectionFlorian Wagenlehner, Caroline R Perry, Thomas M Hooton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 2019
An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male SubjectsAndrew W Harrell, Robert Wilson, Yau Lun Man, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 11, 2021
An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized TrialAnthony Cahn, J Nicole Hamblin, Jon Robertson, et al.
Pulmonary Pharmacology & Therapeutics|February 25, 2023
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta SyndromeMalcolm Begg, Augustin Amour, Emily Jarvis, et al.
Thorax|January 25, 2019
Use of autologous <sup>99m</sup>Technetium-labelled neutrophils to quantify lung neutrophil clearance in COPDNicola Tregay, Malcolm Begg, Anthony Cahn, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Sexual Medicine|July 22, 2025
Mindfulness and daily sexual function: a dyadic diary studyEmily Jarvis, Jackie S Huberman, Natalie O Rosen
Clinical Therapeutics|July 30, 2018
Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy SubjectsRobert Wilson, Emily Jarvis, Mickael Montembault, et al.
Contemporary Clinical Trials Communications|December 16, 2025
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3Florian Wagenlehner, Keith S Kaye, David A Talan, et al.
Respiratory Research|May 13, 2022
Mass spectrometry detection of inhaled drug in distal fibrotic lungTheresia A Mikolasch, Eunice Oballa, Mitra Vahdati-Bolouri, et al.
Lancet (London, England)|February 11, 2024
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trialsFlorian Wagenlehner, Caroline R Perry, Thomas M Hooton, et al.
Future Microbiology|February 24, 2025
Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infectionFlorian Wagenlehner, Caroline R Perry, Thomas M Hooton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 2019
An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male SubjectsAndrew W Harrell, Robert Wilson, Yau Lun Man, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 11, 2021
An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized TrialAnthony Cahn, J Nicole Hamblin, Jon Robertson, et al.
Pulmonary Pharmacology & Therapeutics|February 25, 2023
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta SyndromeMalcolm Begg, Augustin Amour, Emily Jarvis, et al.
Thorax|January 25, 2019
Use of autologous <sup>99m</sup>Technetium-labelled neutrophils to quantify lung neutrophil clearance in COPDNicola Tregay, Malcolm Begg, Anthony Cahn, et al.
Pageof 2